Cargando…
Whether, when, how, and how much? General public’s and cancer patients’ views about the disclosure of genomic secondary findings
BACKGROUND: Data on the modalities of disclosing genomic secondary findings (SFs) remain scarce. We explore cancer patients’ and the general public’s perspectives about disclosing genomic SFs and the modalities of such disclosure. METHODS: Sixty-one cancer patients (n = 29) and members of the public...
Autores principales: | Cléophat, Jude Emmanuel, Dorval, Michel, El Haffaf, Zaki, Chiquette, Jocelyne, Collins, Stephanie, Malo, Benjamin, Fradet, Vincent, Joly, Yann, Nabi, Hermann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236159/ https://www.ncbi.nlm.nih.gov/pubmed/34174888 http://dx.doi.org/10.1186/s12920-021-01016-8 |
Ejemplares similares
-
Canadian Healthcare Professionals’ Views and Attitudes toward Risk-Stratified Breast Cancer Screening
por: Lapointe, Julie, et al.
Publicado: (2023) -
Calcifediol: Why, When, How Much?
por: Donati, Simone, et al.
Publicado: (2023) -
Vitamin D Deficiency in Development: How Much Is Enough, and How Much Is Too Much?
por: Mandell, Erica W.
Publicado: (2021) -
How Much Drool Is Too Much?()
por: Schubert, Gena, et al.
Publicado: (2019) -
Endoscopic Stenting in Hilar Cholangiocarcinoma: When, How, and How Much to Drain?
por: Tringali, Andrea, et al.
Publicado: (2019)